Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540203 | 0.86 | NQO1 (0.52) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5544085 | 0.80 | PLK1 (0.47) | SMN1; SMN2S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6715388 | 0.79 | S1PR1 (0.49) | KDM4EHIF1AS1PR2S1PR1S1PR3 | |
| SCHEMBL1987105 | 0.78 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL12954755 | 0.78 | S1PR2 (0.56) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL10052930 | 0.77 | S1PR2 (0.55) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL11622628 | 0.77 | TSHR (0.53) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL1367833 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL5535543 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL4633460 | 0.75 | LMNA (0.47) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SMN1; SMN2 3985/4885KDM4E 4854/4885CYP1A2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.